This upcoming Sunday, the people of Venezuela will hold an election that, if legitimate, would put an end to years of the oppressive Maduro narco-regime. U.S. Senator Marco Rubio (R-FL) issued a statement in support of the Venezuelan people: “The...
NOTICIAS
Últimas Noticias
Rubio: “La Tenacidad y Valentía del Pueblo venezolano Estarán a la Vista”
Este próximo domingo, el pueblo venezolano tendrá una elección que, de ser legítima, pondría fin a años de opresión por parte del narco-régimen de Maduro. El senador estadounidense Marco Rubio (R-FL) grabó un mensaje de video en español y emitió una declaración en...
Rubio, Scott, Colleagues to Biden Admin: No Privileges Should Be Given to 9/11 Terrorist
Twenty-three years ago, the United States was attacked by Islamic terrorists on September 11, 2001. Now, Zacarias Moussaoui, the only person convicted in a U.S. court for his role in the attack, has requested the U.S. Department of Justice to allow a prisoner transfer...
Next Week: Rubio Staff Hosts Mobile Office Hours
U.S. Senator Marco Rubio’s (R-FL) office will host virtual Mobile Office Hours next week to assist constituents with federal casework issues in their respective local communities. These office hours offer constituents who do not live close to one of Senator Rubio’s...
Rubio, Colleagues Introduce Ensuring Continuity in Veterans’ Health Act
As the U.S. Department of Veterans Affairs (VA) opens up new facilities, many veterans are losing access to the VA’s Community Care Program and, consequently, their long-term healthcare providers. Veterans throughout the country have reported a loss of care, including...
Rubio Introduces Bill to Strengthen U.S.-India Security Partnership
The U.S.-India partnership is vital to countering influences from Communist China. In order to strengthen this partnership, it is essential to enhance our strategic diplomatic, economic, and military relationship with New Delhi. U.S. Senator Marco Rubio (R-FL)...
Rubio, Coons Introduce Legislation to Improve Domestic Biopharmaceutical Manufacturing Capabilities for Emerging Public Health Threats
Washington, D.C. — U.S. Senators Marco Rubio (R-FL) and Chris Coons (D-DE) introduced the Agility in Manufacturing Preparedness Act (S.3553) to require the U.S. Department of Health and Human Services (HHS) and the Biomedical Advanced Research and Development Authority (BARDA) to contract with the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) for the purpose of evaluating the current capacity and vulnerabilities of biopharmaceutical manufacturing in the United States. NIIMBL is a public-private partnership focused on improving manufacturing capabilities through its cutting-edge expertise, which would help the federal government enhance its preparedness and response capabilities for emerging public health threats. Rubio and Coons first introduced this bill as an amendment (#1917) to the Senate’s Endless Frontier Act in May 2021.
“America needs to be able to make things again, especially medicine,” Rubio said. “My new bill will help bring that back.”
“The current global health crisis has once again underscored the importance of sustained attention to potential threats and our preparedness for them. Expanding our manufacturing capacity in the United States and ensuring that it can respond to a variety of threats is imperative,” Coons said. “The Agility in Manufacturing Preparedness Act will put us in a position to improve our medical preparedness and support America’s health.”
The legislation specifically requires NIIMBL, in partnership with HHS, to:
- Review current domestic biopharmaceutical manufacturing capacity at HHS and its adaptability to various threats;
- Draft recommendations for developing, demonstrating, deploying, and advancing new domestic biopharmaceutical manufacturing technologies that address gaps in HHS’ current capabilities;
- Aligns federal technologies with private-sector capabilities, including those through BARDA’s new BioMAP initiative; and
- Identifies other opportunities and priorities to improve U.S. public health, medical preparedness and response capabilities, and domestic biopharmaceutical manufacturing capabilities.